2 completed, 1 recruiting. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Clinton Bahler: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of OTL78 0.06 mg/kg ZOPOCIANINE given 1-7 days prior to surgery - Prostate Cancer Surgery, Prostate Cancer Metastatic Disease | Phase 2 / Phase 3 | Recruiting | Clinton Bahler | 45 | 2026-12-01 | 2026-10-22 |
| Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection 0.03mg/kg ZOPOCIANINE given day of surgery, 0.06mg/kg ZOPOCIANINE given day of surgery, 0.03mg/kg ZOPOCIANINE given day prior to surgery - Prostate Cancer Surgery, Prostate Cancer Metastatic Disease | Phase 2 | Completed | Clinton Bahler | 22 | 2025-04-02 | 2026-08-13 |
| The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer 68Ga-PSMA-11 PET Scan - Prostate Cancer | Phase 2 | Completed | Clinton Bahler | 51 | 2021-06-11 | 2023-08-03 |
United States (3)
Clint Bahler, MD (2)